Long-term limb allograft survival using anti-CD401, antibody in a murine model

Transplantation

Volumn 75, Issue 5, 2003, Pages 644-650

  Tung, Thomas H H ^a   Mackinnon, Susan E ^a   Mohanakumar, T ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD40 LIGAND MONOCLONAL ANTIBODY;

ADOLESCENT; ALLOTRANSPLANTATION; ANIMAL CELL; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BONE MARROW; CHIMERA; CHRONIC GRAFT REJECTION; CONTROLLED STUDY; FLOW CYTOMETRY; GRAFT REJECTION; GRAFT SURVIVAL; HINDLIMB; HISTOPATHOLOGY; IMMUNOLOGICAL TOLERANCE; MOUSE; MUSCLE TRANSPLANTATION; NONHUMAN; PRIORITY JOURNAL; SKIN TRANSPLANTATION;

ANIMALS; ANTIBODIES, MONOCLONAL; CD40 LIGAND; CONTROL GROUPS; CRICETINAE; GRAFT REJECTION; GRAFT SURVIVAL; HINDLIMB; MICE; MICE, INBRED BALB C; MUSCLE, SKELETAL; SKIN TRANSPLANTATION; TIME FACTORS; TRANSPLANTATION, HOMOLOGOUS; TRANSPLANTATION, ISOGENEIC;

EID: 0037444003     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.TP.0000053756.90975.8E     Document Type: Article

References (66)

1. Nagano H, Tilney NL. Chronic allograft failure: the clinical problem. Am J Med Sci 1997; 313: 305.
2. Monaco AP, Burke JF, Ferguson RM, et al. Current thinking on chronic renal allograft rejection: issues, concerns, and recommendations from a 1997 roundtable discussion. Am J Med Sci 1999; 33: 150.
3. Halloran PF, Melk A, Barth C. Rethinking chronic allograft nephropathy: the concept of accelerated senescence. J Am Soc Nephrol 1999; 10: 167.
4. Aradhye S, Turka LA. Will tolerance become a clinical reality? Am J Med Sci 1997; 313: 310.
5. Kawai T, Andrews D, Colvin RB, et al. Thromboembolic complications after treatment with monoclonal antibody against CD40 ligand. Nat Med 2000; 6: 114.
6. Larsen CP, Elwood ET, Alexander DZ, et al. Long-term acceptance of skin and cardiac allografts after blocking CD40 and CD28 pathways. Nature 1996; 381: 434.
7. Kirk AD, Burkly LC, Batty DS, et al. Treatment with humanized monoclonal antibody against CD154 prevents acute renal allograft rejection in nonhuman primates. Nat Med 1999; 5: 686.
8. Larsen CP, Alexander DZ, Hollenbaugh D, et al. CD40-gp39 interactions play a critical role during allograft rejection. Transplantation 1996; 41: 4.
9. Larsen CP, Pearson TC. The CD40 pathway in allograft rejection, acceptance, and tolerance. Curr Opin Immunol 1997; 9: 641.
10. Kirk AD, Harlan DM, Armstrong NN, et al. CTLA4-Ig and anti-CD40 ligand prevent renal allograft rejection in primates. Proc Natl Acad Sci U S A. 1997; 94: 8789.
11. Durham MM, Bingaman AW, Adams AB, et al. Administration of anti-CD40 ligand and donor bone marrow leads to hemopoietic chimerism and donor-specific tolerance without cytoreductive conditioning. J Immunol 2000; 165: 1.
12. Wekerle T, Sykes M. Mixed chimerism as an approach for the induction of transplantation tolerance. Transplantation 1999; 68: 459.
13. Wekerle T, Kurtz J, Ito H, et al. Allogeneic bone marrow transplantation with costimulatory blockade induces macrochimerism and tolerance without cytoreductive host treatment. Nat Med 2000; 6: 464.
14. Min Z, Jones NF. Limb transplantation in rats: immunosuppression with FK-506. J Hand Surg 1995; 20A: 77.
15. Doi K. Homotransplantation of limbs in rats. Plast Reconstr Surg 1979; 64: 613.
16. Kim SK, Aziz S, Oyer P, et al. Use of cyclosporine-A in allotransplantation of rat limbs. Ann Plast Surg 1984; 12: 249.
17. Press BH, Sibley RK, Shons AR. Limb allotransplantation in the rat: extended survival and return of nerve function with continuous cyclosporine/prednisone immunosuppression. Ann Plast Surg 1986; 16: 313.
18. Guzman-Stein A, Shons AR. Functional recovery in the rat limb transplant model: a preliminary study. Transplant Proc 1987; 19: 1115.
19. Kuroki H, Ikuta Y, Akiyama M. Experimental studies of vascularized allogeneic limb transplantation in the rat using a new immunosuppressive agent FK-506: morphological and immunological analysis. Transplant Proc 1989; 21: 3187.
20. Tung THH, Mohanakumar T, Mackinnon SE. Development of a mouse model for heterotopic limb and composite-tissue transplantation. J Reconstr Microsurg 2001; 17: 267.
21. Tung TH, Mohanakumar T, Mackinnon SE. A subcutaneous heterotopic limb transplantation model in the mouse for prolonged allograft survival. Microsurgery 2001; 21: 298.
22. Hettiaratchy S, Butler PEM, Lee WP. Lessons from hand transplantations. Lancet 2001: 357.
23. Kann BR, Hewitt CW. Composite tissue (hand) allotransplantation: are we ready? Plast Reconstr Surg 2001; 107: 1060.
24. Cooney WP. Successful hand transplantation: one-year follow-up. N Engl J Med 2001; 344: 65.
25. Tobin GR, Granger DK, Breidenbach WC. Hand transplantation follow-up. Lancet 2001; 358: 1018.
26. Manske PR: Hand transplantation [editorial]. J Hand Surg 2001; 26A: 193.
27. Foucher G. Prospects for hand transplantation. Lancet 1999; 353: 1286.
28. Francois CG, Breidenbach WC, Maldonado C, et al. Hand transplantation: comparisons and observations of the first four clinical cases. Microsurgery 2000; 20: 360.
29. Lundborg G. Hand transplantation [editorial]. Scand J Plast Reconstr Surg 1999; 33: 369.
30. Lee WPA, Mathes DW. Hand transplantation: pertinent data and future outlook. J Hand Surg 1999; 24A: 906.
31. Siegler M. Ethical issues in innovative surgery: should we attempt a cadaveric hand transplantation in a human subject? Transplant Proc 1998; 30: 2779.
32. Womer KL, Lee RS, Madsen JG, et al. Tolerance and chronic rejection. Phil Trans R Soc Lond B 2001; 356: 727.
33. Tejani A, Emmett L. Acute and chronic rejection. Semin Nephrol 2001; 21: 498.
34. Kirk AD. Transplantation tolerance: a look at the nonhuman primate literature in the light of modern tolerance theories. Crit Rev Immunol 1999; 19: 349.
35. Dong VM, Womer KL, Sayegh MH. Transplantation tolerance: the concept and its applicability. Pediatr Transplant 1999; 3: 181.
36. Elwood ET, Larsen CP, Cho HR, et al. Prolonged acceptance of concordant and discordant xenografts with combined CD40 and CD28 pathway blockade. Transplantation 1998; 65: 1422.
37. Kenyon NS, Fernandez LA, Lehmann R, et al. Long-term survival and function of intrahepatic islet allografts in baboons treated with humanized anti-CD154. Diabetes 1999; 48: 1473.
38. Szabolcs MJ, Cannon PJ, Thienel U, et al. Analysis of CD154 and CD40 expression in native coronary atherosclerosis and transplant associated coronary artery disease. Virchows Arch 2000; 437: 149.
39. Gaweco AS, Mitchell BL, Lucas BA, et al. CD40 expression on graft infiltrates and parenchymal CD154 (CD40L) induction in human chronic renal allograft rejection. Kidney Int 1999; 55: 1543.
40. Shimizu K, Shonbeck U, Mach F, et al. Host CD40 ligand deficiency induces long-term allograft survival and donor-specific tolerance in mouse cardiac transplantation but does not prevent graft arteriosclerosis. J Immunol 2000; 165: 3506.
41. Elster EA, Blair PJ, Kirk AD. Potential of costimulation-based therapies for composite tissue allotransplantation. Microsurgery 2000; 20: 430.
42. Lee WP. What's new in plastic surgery. J Am Coll Surg 2002; 194: 324.
43. Mathes DW, Randolph MA, Lee WP. Strategies for tolerance induction to composite tissue allografts. Microsurgery 2000; 20: 448.
44. Suzuki H, Hewitt CW, Tran HS, et al. Composite tissue/vascularized bone marrow transplantation: a hierarchy of tissue tolerogenicity. Graft 1999; 2: 111.
45. Lee WP, Yaremchuk MJ, Pan YC, et al. Relative antigenicity of components of a vascularized limb allograft. Plast Reconstr Surg 1991; 87: 401.
46. Buttemeyer R, Jones NF, Min, et al. Rejection of the component tissues of limb allografts in rats immunosuppressed with FK-605 and Cyclosporine. Plast Reconstr Surg 1996; 97: 139.
47. Russell PS, Chase CM, Sykes M, et al. Tolerance, mixed chimerism, and chronic transplant arteriopathy. J Immunol 2001; 167: 5731.
48. Prabhune KA, Gorantla VS, Maldonado C, et al. Mixed allogeneic chimerism and tolerance to composite tissue allografts. Microsurgery 2000; 20: 441.
49. Exner BG, Acholonu I, Ildstad ST. Hematopoietic chimerism, tolerance induction and graft-versus-host disease: considerations for composite tissue transfer. Transplant Proc 1998; 30: 2718.
50. Wekerle T, Sachs DH, Sykes M. Mixed chimerism for the induction of tolerance: potential applicability in clinical composite tissue grafting. Transplant Proc 1998; 30: 2708.
51. Black KS, Hewitt CW, Frazer LA, et al. Composite tissue (limb) allografts in rats. II. Indefinite survival using low-dose cyclosporine. Transplantation 1985; 39: 365.
52. Hewitt CW, Black KS, Dowdy SF, et al. Composite tissue (limb) allografts in rats. III. Development of donor-host lymphoid chimeras in long-term survivors. Transplantation 1986; 41: 39.
53. Hewitt CW, Ramsamooj R, Patel MP, et al. Development of stable mixed T cell chimerism and transplantation tolerance without immune modulation in recipients of vascularized bone marrow allografts. Transplantation 1990; 50: 766.
54. Schuster KM, Hewitt CW. Basic science foundation for clinical composite tissue transplantation. Transplant Proc 2001; 33: 1717.
55. Nikolic B, Sykes M. Bone marrow chimerism and transplantation tolerance. Curr Opin Immunol 1997; 9: 634.
56. Starzl TE, Demetris AJ, Murase N, et al. The lost chord: microchimerism and allograft survival. Immunol Today 1996; 17: 577.
57. Wood KJ, Sachs DH. Chimerism and transplantation tolerance: cause and effect. Immunol Today 1996; 17: 584.
58. Monaco AP, Maki T, Hale D, et al. The enigma of tolerance and chimerism: variable role of T cells and chimerism in induction of tolerance with bone marrow. Transplant Proc 2001; 33: 3837.
59. Donckier V, Toungouz M, Goldman M. Transplantation tolerance and mixed chimerism: at the frontier of clinical application. Transpl Int 2001; 14: 1.
60. Hall BM. Mechanisms of induction of tolerance to organ allografts. Crit Rev Immunol 2000; 20: 267.
61. Caillat-Zucman S. The paradox of chimerism: induction of tolerance or cause of autoimmunity. Adv Nephrol Necker Hosp 1999; 29: 149.
62. Khan A, Tomita Y, Sykes M. Thymic dependence of loss of tolerance in mixed allogeneic bone marrow chimeras after depletion of donor antigen. Transplantation 1996; 62: 380.
63. Bemelman F, Honey K, Adams E, et al. Bone marrow transplantation induces either clonal deletion or infectious tolerance depending on the dose. J Immunol 1998; 160: 2645.
64. + immune regulatory cells are required for introduction of tolerance to alloantigens via costimulatory blockade. J Exp Med 2001; 193: 1311.
65. Kishimoto K, Dong VM, Issazadeh S, et al. The role of CD154-CD40 versus CD28-B7 costimulatory pathways in regulating allogeneic Th1 and Th2 responses in vivo. J Clin Invest 2000; 106: 63.
66. Waaga AM, Gasser M, Laskowski I, et al. Mechanisms of chronic rejection. Curr Opin Immunol 2000; 12: 517.